PF-06730512

N/A

Report date: 2023/04/11 20:00:23

Base Information

Drug NamePF-06730512
Drug Alias NamePF-06730512
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionSlit homolog 2 protein antagonists
TargetsSlit homolog 2 protein
Therapy Area/IndicationsGlomerulosclerosis, Focal Segmental
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[14] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsGlomerulosclerosis, Focal Segmental
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A